



### Millichip Suite

7th November 2025, 10:00 to 16:30

West Bromwich Albion Football Club

#### Working in partnership

Sandwell and West Birmingham Hospitals NHS Trust, The Dudley Group NHS Foundation Trust, The Royal Wolverhampton NHS Trust and Walsall Healthcare NHS Trust







#### **Breakout Session**

Richardson Suite — (Main Room, 1st floor, Amit Rath)

(A)ENT: Mr. J. Murphy

(B)Ophthalmology: Mr. J. Barry

Millichip Suite (Main Room, 1st floor, Gurpreet Rai)

(A)Colorectal: Mr. Ben Liu/Mr. M.Tayyab

(B)Gynaecology: Mr. Ayman Ewies

Bassett Suite (2nd Floor – Lola Omotoso)

(A)General Surgery: Mr. S. Mirza

(B)Peri-operative Assessment: Dr A. Pierson

Pennington Suite (2nd Floor – Alima Bibi)

(A)Breast Unit/DIEP: P. Browne/A. Alam

(B)Lung Screening: E. Gilliland






## **Evolved Colorectal Pathways**

Building on collaborative achievements

Mr. Ben Liu

**BCPC Clinical lead, Consultant Colorectal Surgeon** 



Sandwell and West Birmingham Hospitals NHS Trust, The Dudley Group NHS Foundation Trust, The Royal Wolverhampton NHS Trust and Walsall Healthcare NHS Trust











#### **Colorectal Work Streams**

- Faecal Immunochemistry (FIT) pathways
- Advanced colorectal cancer
- Early rectal cancer
- Anal Intraepithelial Neoplasia (AIN)
- NBOCA
- Robotics
- Same day staging CT & MRI sans






#### **Colorectal Successes**

- Implementation of FIT
- Successful outcomes in diagnostic speed
- Colorectal Workshop
- Development of AIN pathway
- Keeping advance colorectal cancer work in the Black Country
- Beginning to standardize early rectal cancer
- Implementation of ERAS and impact on GIRFT





### FIT – Faecal Immunochemistry Pathways in the Black Country






### FIT: A national directive with local adaptation & execution



- Faecal Immunochemistry Test (FIT) has high sensitivity for detecting colorectal cancer (CRC)
- FIT stratify CRC risks to guide urgency of investigations
- FIT referral guidelines were published in August 2022, enshrined in NICE and then mandated by NHSE
- BCPC colorectal network has produced and implemented its own FIT pathway in April 2023 adhering to the national directives and integrating with our own CRC FDS strategy
- Strong partnerships were forged with our Primary Care partners



#### APPENDIX 2: BLACK COUNTRY ICB FIT POSITIVE 2WW REFERRAL FORM

#### $\underline{\textit{FIT POSITIVE}}~\textbf{2WW URGENT REFERRAL FOR SUSPECTED COLORECTAL CANCER IN ADULTS}$

	NHS
E	England
	Midlands

Patient Details:		Registered GP Details:	
Surname:	Forename:		
DoB:	Gender:		
Ethnicity:		Fax no:	
Address:		Telephone:	
		Email: Date of Decision to refer:	_
Hospital/NHS n	umber:	Date of referral:	
Landline numb	er:	Name of referring GP:	
Mobile number		GP Signature:	
(The patient consen	s to be contacted by text on the above mobile? Yes No )		
Interpreter requ	ired? Y/N First Language:		
atient has capa	city to consent? Y/N		

#### GP Declaration

I have informed the patient they have symptoms which may be caused by cancer, that they are being referred to the rapid access suspected cancer clinic and the nature of the tests likely to take place. I have provided the patient with a 2 week wait information leaffer.

	FIT POSITIVE PATHWAY – URGENT SUSPECTED  Patients MUST be aged 40 years or over with a pore of the fresult and have one or more of the fre	Tick if Present Please include FIT value	
1.	Rectal bleeding with 2 or more episodes in a ≥ 4 week perio abdominal pain.	FIT result:	
2.	Change in bowel habit (looser/more frequent) ≥ 6 weeks v abdominal pain.	FIT result:	
3.	Unexplained/Unintentional weight loss (>10% drop in body w with or without unexplained abdomina	eight) Please specify: kg il pain.	FIT result:
4.	Unexplained and <u>un-investigated in the last 3 years</u> Iron Deficiency Anaemia in men or non-menstruating women.	FIT result:	
٠	Reasons for why FIT was not possible in this patient		

	ANY ADULT (16 years or over) PLEASE REFER FOR FIT TEST THE SAME TIME AS THE REFERRAL. DO NOT WAIT FOR FIT RESULT.	
5.	Abdominal Mass.	
6.	Unexplained rectal mass	
7.	Anal ulceration/mass	


PLEASE ENSURE AN UP TO DATE (WITHIN 3 MONTHS) FULL BLOOD COUNT IS AVAILABLE ON REFERRAL and U+E's

V1, 20.10.2022 Page 1 of






#### FIT Adoption: Exceeding Expectations







#### FDS 28 day targets







#### Repeat FIT: evidence vs pragmatism

#### Evidence

- A single negative FIT has NPV of > 99.5%
- Two negative FIT reduces colorectal cancer probability to 0.04%
- A repeat FIT captured 7% of cancers that is otherwise missed on a single neg FIT (East Lancashire)

#### Current practice at Black Country ICB


TWO negative FIT – review in colorectal clinic at 8 weeks timeframe

#### Pragmatism

- Admin and logistic difficulties from Primary Care
- Concerns about adequacy of patient tracking and patient compliance
- Delays between having first neg FIT result and getting patient to submit second FIT



# FIT negatives: Decision Tree







#### FIT negatives:

### Referral pathway



#### FIT NEGATIVE REFERRAL FOR ADULTS



*				Midlar
٦	Patient Details:		Registered GP Details:	
	Surname:	Forename:		
	DoB:	Gender:		
	Ethnicity:		Fax no:	
	Address:		Telephone:	
	Addicasi		Email:	
			Date of Decision to refer:	
	Hospital/NHS number	:	Date of referral:	
	Landline number:		Name of referring GP:	
	Mobile number:		GP Signature:	
	(The patient consents to be	contacted by text on the above mobile? Yes <u>l. No</u> ii)		
	Interpreter required?	Y/N First Language:		
	Patient has capacity to	consent? Y/N		

#### PLEASE REVIEW FIT NEGATIVE FLOWCHART ON PAGE 3 of SOP

	Referral Pathways	Please include FIT value					
	Urgent Referral to Gastroenterology						
	Patients aged ≥ 40 years with negative FIT (<10 ug HB/g) results and the fo						
1.	Change in bowel habit ≥ 6 weeks	FIT result:					
	Fast Track Referral for Flexible Sigmoidoscopy						
	Patients aged ≥ 40 years with negative FIT (<10 ug HB/g) results and the fo	ollowing:					
2.	Rectal bleeding with 2 or more episodes for ≥ 4 weeks	FIT result:					
	Urgent OGD and Colonoscopy						
	Patients aged ≥ 40 years with negative FIT (<10 ug HB/g) results and the fo	ollowing:					
3.	Unexplained AND <u>un-investigated in the last year</u> Iron Deficiency Anaemia in men or non-menstruating women.  Hbg/dl MCV	FIT result:					
٥.	Ferritin						
	Direct CT Thorax Abdomen & Pelvis Requests or NSS (non-specific symptor	ns) referral					
	Patients aged ≥ 40 years with negative FIT (<10 ug HB/g) results and the f						
١.	Abdominal mass	FIT result:					
4.	OR						
	Weight loss ((either documented >5% in three months or with strong clinical suspicion)						







#### FIT Negatives: Tracking Progress

- Drafted New SOP
- Ratified at Colorectal Network Workshop June 2025
- Developed further with West Midlands Cancer Alliance
- Approved at executive level across all 4 Trusts
- Discussed at Black Country Professional Engagement
- Consensus reached with Black Country Primary Care Collaborative, COMMS circulated
- Disseminated to Black Country Primary Care LMC (local medical committee) and Black Country Cancer Board for Final approval
- Aim to have 3 months grace period for extraction of existing/old pathways
- Completed BCPC algorithm now leading as the template for WMCA's own FIT pathway development





### Squamous intraepithelial lesions of anus and peri-anus

Ms. Maria Mondragon


**Consultant Colorectal Surgeon, RWT** 





#### **Preliminary AIN Pathway**

Pathway for suspected cases of Anal squamous intraepithelial lesions (SIL)







#### **Early Rectal Cancer**

- All 4 Trusts provide early rectal cancer treatments
- Highly variable practices, diagnoses, patient selection, operative techniques, outcome measurements and salvage plans
- Mr Pereira has made ICB wide systematic enquiries about current practices and agreement on common standards

#### Early Rectal Cancer Treatment Practices Survey

Instructions to respondent:

Please fill in this questionnaire based on your hospital's current standard practice for early rectal cancer (e.g. T1-T2 with no distant metastases). If certain options are not applicable, please mark "N/A". Feel free to add comments or explain divergences from standard pathways.

Section A: Institutional / Respondent Details 1. Hospital name:
2. Number of rectal cancer cases treated per year:
3. Number of early rectal cancer (T1-T2) cases treated per year:
4. Roles of respondent(s):
Section B: Diagnosis & Staging
5. What imaging studies are routinely used for staging early rectal cancer? (Tick all that apply)
- MRI pelvis
- Endorectal ultrasound (ERUS) - CT chest / abdomen / pelvis
- Colonoscopy with biopsy
- PET-CT
- Others (please specify):
6. Criteria used to define "early rectal cancer" in your practice: (Tick all that apply) - T1 only
- T1 with favourable histology (e.g. low grade, no lymphovascular invasion)
- T2 without suspected lymph node involvement
- Maximum tumour size threshold (specify): cm
- Distance from anal verge threshold: cm
- Other criteria:
Section C: Treatment Pathways
7 What are the treatment ontions your hospital offers for early rectal cancer? (Tick all

What are the treatment options your hospital offers for early rectal cancer? (Tick all that apply)





#### **NBOCA - National Bowel Cancer Audit**


#### Up to Q2 of 2024

	Adjuvant chemo for Stage 3 cancer	Seen by colorectal CNS	30-day Emergency readmission	Unplanned return to theatres	90 days mortality after major colorectal cancer resections
Wolverhampton	55.0%	98.0%	10.4%	9.1%	1.80%
Walsall	69.0%	97.0%	13.0%	8.6%	4.60%
Dudley	56.0%	94.0%	14.3%	7.7%	4.90%
Sandwell	37.0%	97.0%	9.3%	8.3%	4.50%





#### NBOCA: 90-day mortality after major resection





#### State of Nation (Annual) Report 2024 KPIs & Benchmark

Source: NBOCA





Cancer Alliance/ Trust Name	Clinical Nurses	Rectal cancer volume	90 days mortality	30 day return to theatre	30 day readmissio n	Stoma unclosed at 18 month	Adj. chemo for Stage 3	Toxicity	Neoadj. for rectal cancers	2-year survival	Number of targets met
Local target Overall % meeting target England % meeting target Wales % meeting target	>95% 61 62 40	≥20 cases 81 81 80	≤6% 96 96 100	≤10% 92 92 100	≤15% 81 81 90	≤35% 41 42 20	>50% 93 94 100	<33% 95 97 100	10-60% 89 89 90	>70% 97 97 100	
			West	Midland	s: Black	Country	У				
Dudley Group NHS Foundation Trust	95	31	6.3	8.4	14.0	49	69	17	22	68.5	7
Royal Wolverhampton NHS Trust	96	36	2.7	5.0	9.6	33	76	20	45	91.1	10
Walsall Healthcare NHS Trust	92	22	5.4	10.4	17.1	41	66	19	33	70.4	6
Sandwell and West Birmingham Hospitals NHS Trust	88	26	2.0	8.2	8.7	55	58	no data	46	88.5	7



#### Black Country Provider Collaborative Advanced Colorectal Cancers












#### **ERAS and GIRFT**

- Enhanced recovery after surgery templates were locally adapted in all 4 colorectal units in 2023
- Dedicated ERAS team nurses and practitioners were recruited
- Remote monitoring implemented
- Target-driven discharge criteria are being trialed



Referral for Anaesthetic Assessment






#### Median length of stay for elective resection for colon cancer -12 months to Qtr end

Period	Benchmark	Midlands	BC	RWT	SWB	DGH	WHT
Q3 23-24	5.0	5.5	6.0	6.0	4.0	6.0	6.0
Q3 24-25	5.0	5.5	4.5	5.0	4.0	5.0	4.0
Change	→0.0	→0.0	<b>₩-1.5</b>	₩-1.0	→0.0	₩-1.0	₩-2.0

System Value: 4.5 Peer Median: 5.5 Benchmark: 5.0

As a system and as trusts, we are meeting the benchmark with Wolverhampton, Dudley and Walsall all improving in the last 12 months.

#### **ICB Variation**




#### **Provider Variation**



#### Source:

View metric - Median length of stay for elective resection for colon cancer (12mths to qtr end) - Model Health System







# Thank you & Questions.

https://blackcountryprovidercollaborative.nhs.uk/





### Colorectal Improvement Project

Mr. M Tayyab

**Colorectal Lead** 

**Walsall Manor Hospital** 







2022 Financial year	NBOCA-National Average published July 2023	Figures presented by project team 01/01/2022 - 31/05/2023 (Based on only major resections)
Total patients operated on during this timeframe		
Proportion of patients having emergency Major resection	14%	39.20%
Adverse event rate following elective major resection for colorectal CA	14(GIRFT)	14.50%
Adverse event rate following elective major resection for rectal CA	20(GIRFT)	29.40%
Length of stay > 5 days	<60%	73.40%
30-day post-op mortality	1.70%	6.30%
90-day post-op mortality	2.80%	10.90%
30-day readmission excluding 0 days LOS	12.50%	14.10%
30-day readmission including 0 days LOS		21.90%
30-day unplanned return to theatre (URTT)	<6.8%	6.30%
lleostomy formation rate at time of anterior resection		56.70%
Cumulative Rectal cancer resection volume**		20 (across 17 Months)







#### Proportion of patients having emergency resections




# Proportion of patients having emergency Major resection











### Length of stay > 5 days







#### Adverse event rate following elective major resection for colon CA



### Adverse events (colon)







#### Adverse event rate following elective major resection for rectal CA




### Adverse events (rectum)







#### 30-day readmission excluding 0 days LOS




## 30-day readmission rate (excluding 0 day)







#### 30-day unplanned return to theatre




### 30-day return to theatre











#### 30 days mortality












#### 90 days mortality







#### Ileostomy formation rate at time of anterior resection



# Ileostomy formation rate at time of anterior resection







Of the 24 patients who died, 20 (83%) were over 70 years old, and 15 (62.5%) were over 80 years old.

15 surgeries (62.5%) were emergency procedures, with the remaining 9 (37.5%) being elective.

Most patients 21/24, 87.5%) were classified as ASA III or above, with 9 (37.5%) classified as ASA IV or above.

9/24 (37.5%) ASA IV patients underwent surgery (six emergency and three elective).

## Demographics and Risk Factors







## Demographics and Risk Factors

5/9 (55.5%) ASA IV patients died within a week of surgery

7/9 (77.7%) ASA IV patients died during their hospital stay.

4/24 (16.6%) elective surgeries were palliative resections performed on patients with metastatic disease.

Only two of ASA IV patients survived for nearly two years, as they were 59 and 69 years old.







## **Challenges Identified**



**Deprivation 25th**most deprived out of 217

most deprived out of 317 Local Authorities

14th

most deprived affecting children out of 317 Local Authorities

01

A significant proportion (62%) of the colorectal cancer population presented as ASA III or above, reflecting the complexity of managing these high-risk patients.

02

Social deprivation is a key factor in Walsall, with a high index level impacting healthcare outcomes. 03

Over 35% of colorectal cancer patients presented as emergencies (e.g., obstruction or perforation), contributing to poor short- and long-term outcomes.

04

No/limited access to bowel stenting









## **Acknowledged Issues**

We recognise that some poor outcomes were influenced by clinical decision-making.

#### Specifically:

- A higher number of resections were performed on palliative patients.
- Major surgeries were sometimes undertaken instead of less invasive palliative approaches to improve comfort.
- Bowel cancer screening patients were taken away from us, but did not get them back.







#### Patients' source

- 1. Emergency Presentation >1/3rd
- 2. Elective pathway <2/3rd
- a. GP referrals (Standardization of 2WW referral pathway)
- b. Bowel cancer screening-Got possibly half of Walsall patients back







## Community / GP engagement

Community
Engagement
and Early
Diagnosis:

Strengthened collaboration with GPs to streamline referrals.

Public awareness campaigns to promote recognition of bowel habit changes and increase participation in bowel cancer screening programs.







## Public campaign on raising cancer awareness- Team









#### **Prehabilitation**

Fit patients -> Exercise / Physio

Less fit→ Community nurse

**Palliative** 

Mechanical/Chemical bowel prep

Role of Geriatric





### Intraoperative







**Dedicated colorectal** anaesthetists



Two surgeons operating



**Nurses training** 

#### Standardised anaesthesia

Spinal Physiological optimization Goal-directed therapy Use of Edwards Adequate analgesia

#### Post operative















COLORECTAL **CONSULTANT WARD ROUND (EVERY DAY)** 

COLORECTAL GRAND **ROUND (FRIDAYS) CHEST** PHYSIO/ MOBILISATION/ **ERAS IMPLEMENTATION** 

THEATRE STAFF **EDUCATION** 

TEAM ENGAGEMENT /CULTURE

MEDICAL INPUT FOR **GENERAL SURGICAL PATIENTS** 

**DEDICATED ENHANCED** LEVEL CARE ( LEVEL 1+)







### QIPS monitoring colorectal improvement project

Consultant ward round in colorectal patients

Medical consultant input in general surgical patients

Standardised colorectal anaesthetist audit

Two surgeons operating for complex colorectal cases

Perioperative care audit

Standardised ward - round for general surgery project







### Targets needing more attention

Community engagement

Dedicated enhanced level care (Level 1+)

Two surgeons operating

Nurses training in theatre

Medical input for surgical patients





### **Emergency presentation**

**DECISION MAKING** 

OPERATING ON PALLIATIVE PATIENTS

PREDICTIVE SCORING SYSTEMS







## QIPS monitoring colorectal improvement project

Consultant ward round in colorectal patients

Medical consultant input in general surgical patients

Standardised colorectal anaesthetist audit

Two surgeons operating for complex colorectal cases

Perioperative care audit


Standardised ward - round for general surgery project







## Median length of stay for elective resection for rectal cancer (12mths to qtr end), National Distribution










Adverse outcome rate following elective resection for rectal cancer (12mths to qtr end)










## Median length of stay for elective resection for colon cancer (12mths to qtr end), National Distribution










Median length of stay for elective resection for colon cancer (12mths to qtr end)




Benchmark

Peers (My System / ICB)





## Adverse outcome rate following elective resection for rectal cancer (12mths to qtr end), National Distribution










Median length of stay for elective resection for rectal cancer (12mths to qtr end)










## Adverse outcome rate following elective resection for colon cancer (12mths to qtr end), National Distribution












Adverse outcome rate following elective resection for colon cancer (12mths to qtr end)










## Emergency readmission within 30 days following elective resection for rectal cancer (12mths to qtr end), National Distribution




Provider Median (16.3%)







Emergency readmission within 30 days following elective resection for rectal cancer (12mths to qtr end)










## Emergency readmission within 30 days following elective resection for colon cancer (12mths to qtr end), National Distribution










Emergency readmission within 30 days following elective resection for colon cancer (12mths to qtr end)











Hospital acquired condition rate for patients during an elective admission for colon cancer (12mths to qtr end), National Distribution



In order of Hospital acquired condition rate for patients during an elective admission for co cancer (12mths to qtr end)(n=121)









# Thank you & Questions.

https://blackcountryprovidercollaborative.nhs.uk/






## Gynaecology

Rebuilding Stronger: GIRFT Insights and Future Pathways

**BCPC Clinical Council Progress Update** 

**Dr. Ayman Ewies** 

**BCPC Clinical lead, Consultant Gynaecologist** 



Sandwell and West Birmingham Hospitals NHS Trust, The Dudley Group NHS Foundation Trust, The Royal Wolverhampton NHS Trust and Walsall Healthcare NHS Trust









## GIRFT Provider Visits – System Summary

- All four Trusts (DGFT, SWBH, WHT, RWT) completed GIRFT on-site reviews (June–August 2025).
- Network received individual feedback letters and a consolidated summary highlighting system-wide themes.

#### **Strengths & Exemplary Practice:**

- DGFT & WHT established day case hysterectomy & achieved short length of stay.
- SWBH is maintaining high ambulatory rates (89%) and robust gynae-oncology provision.
- RWT maintains high patient experience standards through adaptable service delivery despite workforce pressures.
- All sites engaged in productive theatre utilisation and pooled-list working.





## **GIRFT Provider Visits – System Summary**

#### **Challenges / Opportunities:**

- Coding accuracy and data alignment (Model Hospital vs local audits).
- Variable theatre utilisation (55–85%) and recovery setup differences.
- Workforce fragility in radiology, gynaecological oncology and endometriosis services.
- Need for consistent criteria-led discharge and day-case pathways.

#### **Next Step:**

Addressing cross-cutting themes within the network.





## **GIRFT Provider Visits – System Summary**

Theme	DGFT	WHT	SWBH	RWT	System Opportunity
Leadership & Culture	Highly collaborative, stable triumvirate	Excellent MDT culture, high morale	Dynamic, rebuilding after site move	Passionate team under pressure	Leverage strong local leadership to embed shared GIRFT delivery model
Minimal-Access Surgery / LoS	Exemplar LoS ≤ 2 days; skill mix limited (4 lap surgeons)	High MA rate > 70%; LoS ≈ 1 day	39% TLH; Workforce Review	MA ≈ 49%; LoS 2.0–2.2 days	Expand laparoscopic training Workforce Review
Endometriosis	Staffing loss – risk to accreditation	Affiliated to RWT	Accredited Centre	Accredit Centre	System review of sustainable BCES model
Theatre Productivity	82–84% utilisation; pooled lists	92% utilisation; exemplary pooled-list protocol	74–85%; data variation	71–85%; scope to improve TTO & discharge	System theatre productivity benchmarking and sharing of DGFT/WHT models
Outpatients / DNAs / PIFU	DNA 6.4%, PIFU 3%; room to improve	DNA 8.6%, PIFU 7–9%	DNA high; implementing 2-way comms	DNA 7–8%, PIFU 2%	System-wide Outpatient Transformation & unified referral guidance
Cancer & Hysteroscopy	74% OP hysteroscopy; CDC bid approved	80% OP rate; Entonox use expanding	89% OP rate, Centre of Excellence, 1-stop clinic model	Level 2 centre; 1-stop clinic model	Align cancer pathways and hysteroscopy standards across network
Workforce	Lacks dedicated gynae radiologist	Stable workforce, robot BC underway	Shortage of laparoscopic surgeons	Consultant vacancies + reduced capacity	Workforce planning across BCPC





## **Black Country Endometriosis Service** (BCES)

#### **Currently:**

 Updated Service Specification (Feb 2025) endorsed and operational across the four-site model (3 Centres and 1 Unit).

#### **Challenges:**

- Detailed data analysis completed variation in waits, access, and MDT consistency.
- Radiology issue at Dudley.
- Consultant Workforce Issues (One main consultant per centre)





## **Black Country Endometriosis Service** (BCES)

#### **Celebration:**

- Network-wide agreement that service redesign is required to ensure sustainability under forthcoming BSGE standards (2026–27).
- A Comprehensive Discussion Paper for service development has been circulated for consultation.

#### **Next step:**

 Collate consultation feedback and prepare an Executive summary paper outlining potential future configurations.





### **Complex Vulval Services**

#### **Challenges:**

- Service & Leadership gap following the departure of the service lead.
- MDT Coordinator post proposed and included within BCPC funding considerations.

#### **Celebration:**

- Multi-site collaboration and service alignment started (unfortunately, now on hold)
- Patient information leaflets finalised, aligned to national guidelines.

#### **Next step:**

- Replace the vacant post in Pan Birmingham Cancer Centre (difficult at the moment).
- Confirm interim clinical leadership and progress MDT Coordinator funding case for approval.





## Sandwell Hub Development

#### **Celebrating Progress**

- Major milestone in the establishment of the South Black Country Elective Surgical Hub, located at Sandwell Health Campus.
- Gynaecology confirmed as one of the core day-case specialities, alongside General Surgery and Orthopaedics.
- Strong collaboration between SWBH, DGFT, and BCPC teams joint business case submitted and supported at system level.

#### **Next Step**

- The capital allocation bid submitted to NHS England is under national review.
- Once approved, procurement of theatre equipment and instrumentation will begin
  - + estates refurbishment





## Sandwell Hub Development

- Proposed deadline: by end of 2025/26 financial year.
- Phase 1 of implementation: moving SWBH Gynaecology day-case activity to Sandwell theatres.

#### **Challenges**

- Capital approval timelines, national review and procurement lead times may impact start dates.
- Ongoing workforce and capacity planning to support transfer of activity into the hub.

#### **Future Aspirations**

 Use hub development to boost HVLC productivity and theatre utilisation + standardised pathways across south.





## **Overall Summary**

#### **Celebrations:**

- Completion of GIRFT visits across all providers.
- Strong partnership working and clinical engagement.
- Endometriosis service is ready for Executive review.
- Sandwell Hub progress marks a major strategic step forward.

#### **Challenges:**

- Workforce fragility in endometriosis & laparoscopic surgery, radiology gaps, gynaecological oncology, vulva services.
- Variable day-case efficiency and data reconciliation.





## **Overall Summary**

#### **Next Steps:**

- Present System GIRFT Action Plan.
- Agree on the best model for endometriosis service which is safe and productive.
- Continue Hub implementation and align 2025/26 priorities to delivery phase.





# Thank you & Questions.

https://blackcountryprovidercollaborative.nhs.uk/





#### How should we respond to the forthcoming BSGE accreditation standards (2026–27)?

What model will ensure resilience in the Endometriosis and Vulval services long term?

How can the new Sandwell Elective Hub best support high-volume, low-complexity gynaecology?